Searchable abstracts of presentations at key conferences in endocrinology

ea0013p62 | Clinical practice/governance and case reports | SFEBES2007

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia presenting as cyclical Cushings Syndrome

Carty David M , Connell John M

We present the case of a 76 year old woman who was admitted to our hospital with severe Cushings syndrome, in association with hair loss and hypokalaemia. Plasma cortisol levels were elevated, and did not suppress with high dose dexamethasone. ACTH levels were detectable throughout the HDDST. MRI pituitary and CT adrenals were normal, but CT of chest revealed an area of nodularity in the right lung. With no specific treatment her symptoms settled, and her biochemistry returned...

ea0013p159 | Diabetes, metabolism and cardiovascular | SFEBES2007

The interactions between insulin and tumour necrosis factor-alpha in human aortic endothelial cells

Ritchie Stuart , Connell John , Salt Ian

There is a significant body of research that demonstrates an association between central (visceral) obesity, insulin resistance, endothelial dysfunction and accelerated atherosclerosis, but the molecular mechanisms underlying this link are incompletely understood. In cultured human aortic endothelial cell (HAEC) models, insulin stimulates an intracellular signalling cascade resulting in activating phosphorylation of Insulin Receptor Substrate-1, Protein kinase B (PKB/Akt) and ...

ea0034p359 | Steroids | SFEBES2014

Does recurrent hypoglycaemia, a known activator of the HPA axis, alter the diurnal pattern of cortisol release?

George Priya , Mackie Alasdair , Connell John , McCrimmon Rory

In population studies, premature cardiovascular disease is associated with cortisol dysregulation. Recently, recurrent hypoglycaemia in individuals with type 1 diabetes (T1D) was reported to be associated with increase carotid intima–media thickness. Hypoglycaemia is a potent activator of the hypothalamo-pituitary–adrenal axis (HPA axis) with eventual release of cortisol. We hypothesized that individuals with T1D who experience recurrent hypoglycaemia might demonstra...

ea0028p215 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2012

Investigation and Management of Primary Aldosteronism - A Review of Cases and Audit of Outcomes in a Tertiary Referral Centre

Currie Gemma , O'Dwyer Patrick , Connell John , Freel Marie

Primary aldosteronism (PA) accounts for up to 15% of cases of hypertension, and associates with increased cardiovascular morbidity. Specific treatment options include mineralocorticoid antagonists or adrenalectomy; the latter offers cure although reported rates vary between 20–60%. The role of adrenal vein sampling (AVS) in diagnosing PA remains controversial. By reviewing casenotes of PA patients treated surgically and comparing with matched medically managed PA patients...

ea0025oc2.3 | Steroids | SFEBES2011

APEX1, a novel, negative regulator of aldosterone synthase activity, differentially binds to a single nucleotide polymorphism in the aldosterone synthase gene and represses transcriptional activity both in vitro and in vivo

McManus Frances , Sands William , Fraser Robert , Davies Eleanor , Connell John

Aldosterone synthesis is heritable; a single nucleotide polymorphism (SNP) in the promoter of the aldosterone synthase gene (position −344, rs1799998) has been associated with an increased plasma aldosterone levels and hypertension. However, deletion of this site has no effect on gene transcription in vitro and therefore the mechanism that links genotype with phenotype is unclear.We identified a polymorphism at position −1651 T/C (rs13...

ea0021p359 | Steroids | SFEBES2009

Variation in the aldosterone synthase gene may alter gene transcription via altered transcription factor binding

McManus Frances , Sands William , Davies Eleanor , Connell John

The aldosterone synthase gene encodes the final step in the production of aldosterone. The aldoststerone synthase gene is polymorphic and variants within the gene and the regulatory region have been associated with hypertension and a phenotype of relatively higher level of aldosterone and its metabolites. However to date; none of the polymorphisms in the regulatory region of CYP11B2 have been shown to alter transcription. Seven novel polymorphisms in the promoter region of CYP...

ea0013oc1 | Steroid synthesis and action | SFEBES2007

Monogenic polycystic ovary syndrome (PCOS) due to novel mutations in the H6PD gene - apparent cortisone reductase deficiency (ACRD)

Slabbert Ana , Lavery Gareth , Connell John , Walker Elizabeth , Stewart Paul

ACRD presents with clinical features of hyperandrogenism in females similar to those of PCOS (acne, hirsutism, oligomenorrhea, infertility), and precocious puberty in males. Obesity also occurs in some cases. Increased cortisol clearance leads to an increased hypothalamic-pituitary-adrenal axis drive resulting in elevated serum androgen levels and a decreased urinary cortisol metabolite: cortisone metabolite ratio below 0.5 (normal adult range 0.7–1.3). These observations...

ea0049gp58 | Cardiovascular & Lipid Endocrinology | ECE2017

Circulating levels of miR24-1 cluster microRNAs are increased in primary aldosteronism

van Kralingen Josie , Anderson Cali , Freel E. Marie , Connell John M. , MacKenzie Scott M. , Davies Eleanor

Introduction: Measurement of microRNA (miRNA) in aldosterone-producing adenoma (APA) tissue from primary aldosteronism (PA) patients show levels of the miR24-1 cluster miRNAs (i.e. miRNAs 24-1, 27b and 23b) are significantly reduced relative to normal adrenal tissue. Our previous studies also show that miRNA-24 directly targets CYP11B2 (aldosterone synthase) gene expression. Circulating miRNAs released into the bloodstream may be diagnostic biomarkers or signalling mo...

ea0031p316 | Steroids | SFEBES2013

Validation of CYP11B1 and CYP11B2 regulation by microRNA-24

Diver Louise , Alvarez-Madrazo Samantha , Lin Junjun , Wood Stacy , MacKenzie Scott , Connell John , Davies Eleanor

The CYP11B1 and CYP11B2 genes encode the enzymes responsible, respectively, for the terminal stages of cortisol and aldosterone biosynthesis, and have been implicated in the development of essential hypertension. Previously, we investigated the role of microRNAs in the regulation of these genes and showed in vitro that levels of the adrenally-expressed microRNA-24 (miR-24) inversely correlate with those of CYP11B1 and CYP11B2 mRNA, ...

ea0031p326 | Steroids | SFEBES2013

Identification of a novel CYP11B1 isoform in human adrenocortical cells

Alvarez-Madrazo Samantha , MacKenzie Scott , Brinth Alette , Fraser Niall , Bernhardt Rita , Connell John , Davies Eleanor

The final reaction for cortisol production in the adrenal gland is catalysed by the 11β-hydroxylase enzyme, encoded by the CYP11B1 gene. Variants in this gene have been associated with alterations in cortisol levels, which increase blood pressure. This gene is traditionally thought to consist of 9 exons. However, recent evidence has predicted the existence of at least one alternatively spliced form.The presence of novel CYP11B1 mRN...